Mallinckrodt
Acquired5 known investors
Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network. The site serves as a landing page directing visitors to the two separate pharmaceutical companies.
Also known as Ocera Therapeutics · Ocera Therapeutics, Inc.
Investors · 5
Company profile
researched Aug 2026Ocera Therapeutics was a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need. Its lead developmental product, OCR-002, is an ammonia scavenger being studied for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia that arises as a complication of acute or chronic liver disease.
The company was publicly traded on NASDAQ until December 2017, when Mallinckrodt plc completed a tender offer for all outstanding Ocera common stock followed by a merger under Section 251(h) of the Delaware General Corporation Law. Ocera thereby became an indirect, wholly owned subsidiary of Mallinckrodt, and OCR-002 was added to Mallinckrodt's Specialty Brands pipeline.
Latest developments
On December 8, 2017, the tender offer by a Mallinckrodt subsidiary for all outstanding Ocera shares expired, with more than 50% of shares validly tendered (excluding shares tendered by notice of guaranteed delivery). Mallinckrodt announced completion of the acquisition on December 11, 2017. Untendered shares were cancelled and converted into the right to receive $1.52 per share in cash plus one Contingent Value Right for one or more cash payments of up to $2.58 per share. Mallinckrodt expected the acquisition to dilute adjusted diluted earnings per share by $0.25 to $0.35 annually beginning in 2018.
▸Full profile — market position, technology, go-to-market, history
Market position
Ocera operated in the orphan and serious liver disease segment of biopharmaceuticals. Mallinckrodt characterized OCR-002 as a unique, highly durable developmental asset that diversified and expanded its Specialty Brands pipeline, indicating the asset was positioned as a differentiated therapy for hepatic encephalopathy.
Technology
OCR-002 is an ammonia scavenger under clinical development for hepatic encephalopathy, targeting hyperammonemia associated with acute or chronic liver disease.
Go-to-market
Patients with hepatic encephalopathy and other orphan or serious liver diseases with high unmet medical need, treated within specialty and hospital care settings.
History
Ocera Therapeutics was a NASDAQ-listed clinical-stage biopharmaceutical company. Its independent existence ended in December 2017 when it was acquired by Mallinckrodt plc through a tender offer and back-end merger, after which its shares ceased trading on NASDAQ.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsMallinckrodt plc (NYSE: MNK) closed its acquisition of Ocera Therapeutics following a tender offer that expired December 8, 2017, with more than 50% of shares validly tendered. A Mallinckrodt subsidiary merged into Ocera under Section 251(h) of the Delaware General Corporation Law, making Ocera an indirect, wholly owned subsidiary; untendered shares were converted into the right to receive $1.52 per share plus one Contingent Value Right of up to $2.58 per share. Ocera shares ceased trading on NASDAQ.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathyprnewswire.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mallinckrodt do?
- Clinical-stage biopharmaceutical company developing OCR-002 for hepatic encephalopathy; acquired by Mallinckrodt in December 2017.
- Who are Mallinckrodt's investors?
- Mallinckrodt's investors include ARCH Venture Partners, Cross Creek Advisors, Pfizer Venture Investments, Signet Healthcare Partners, Sofinnova Ventures.